Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Express Scripts
Baxter
Merck
McKinsey

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MELOXICAM

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Meloxicam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00034853 Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) Completed Boehringer Ingelheim Phase 3 2000-12-01 To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)
NCT00042068 A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis Completed Boehringer Ingelheim Phase 3 2002-06-01 A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.
NCT00152919 Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy Completed Princess Margaret Hospital, Canada Phase 3 2004-02-01 Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards.
NCT00152919 Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy Completed University Health Network, Toronto Phase 3 2004-02-01 Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards.
NCT00239382 A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis Completed Boehringer Ingelheim Phase 3 2004-07-01 The objective of this trial was to assess the efficacy and safety of 15 mg meloxicam i.m. once daily compared with 15 mg meloxicam tablets once daily p.o. in patients with Rheumatoid arthritis over a time period of 7 days.
NCT00239395 A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis Completed Boehringer Ingelheim Phase 3 2004-07-01 The objective of this trial was to assess the efficacy and safety of 7.5 mg meloxicam i.m. once daily compared with 7.5 mg meloxicam tablets once daily p.o. in patients with osteoarthritis over a time period of 7 days.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Meloxicam

Condition Name

Condition Name for Meloxicam
Intervention Trials
Healthy 18
Osteoarthritis 9
Arthritis, Rheumatoid 7
Migraine 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Meloxicam
Intervention Trials
Osteoarthritis 16
Arthritis, Rheumatoid 10
Osteoarthritis, Knee 9
Arthritis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Meloxicam

Trials by Country

Trials by Country for Meloxicam
Location Trials
United States 122
Japan 20
China 13
Brazil 9
Canada 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Meloxicam
Location Trials
Massachusetts 8
Texas 8
Florida 8
Pennsylvania 6
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Meloxicam

Clinical Trial Phase

Clinical Trial Phase for Meloxicam
Clinical Trial Phase Trials
Phase 4 11
Phase 3 22
Phase 2/Phase 3 1
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Meloxicam
Clinical Trial Phase Trials
Completed 52
Recruiting 14
Not yet recruiting 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Meloxicam

Sponsor Name

Sponsor Name for Meloxicam
Sponsor Trials
Boehringer Ingelheim 29
Iroko Pharmaceuticals, LLC 3
Axsome Therapeutics, Inc. 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Meloxicam
Sponsor Trials
Industry 53
Other 36
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Harvard Business School
Colorcon
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.